Taribavirin (rINN; also known as viramidine, codenamed ICN 3142) is an antiviral drug in Phase III human trials, but not yet approved for pharmaceutical use. It is a prodrug of ribavirin, active against a number of DNA and RNA viruses. Taribavirin has better liver-targeting than ribavirin, and has a shorter life in the body due to less penetration and storage in red blood cells. It is expected eventually to be the drug of choice for viral hepatitis syndromes in which ribavirin is active.

PropertyValue
dbpedia-owl:Drug/atcPrefix
  • J05
dbpedia-owl:Drug/atcSuffix
  • AB04
dbpedia-owl:Drug/casNumber
  • 119567-79-2
dbpedia-owl:Drug/drugbank
  • none
dbpedia-owl:Drug/iupacName
  • 1-[(2R,3R,4S,5S)- 3,4-dihydroxy-5- (hydroxymethyl)oxolan-2-yl]- 1,2,4-triazole-3-carboximidamide
dbpedia-owl:Drug/pubchem
  • 451448
dbpedia-owl:atcPrefix
  • J05
dbpedia-owl:atcSuffix
  • AB04
dbpedia-owl:casNumber
  • 119567-79-2
dbpedia-owl:drugbank
  • none
dbpedia-owl:iupacName
  • 1-[(2R,3R,4S,5S)- 3,4-dihydroxy-5- (hydroxymethyl)oxolan-2-yl]- 1,2,4-triazole-3-carboximidamide
dbpedia-owl:pubchem
  • 451448
dbpedia-owl:thumbnail
dbpprop:abstract
  • Taribavirin (rINN; also known as viramidine, codenamed ICN 3142) is an antiviral drug in Phase III human trials, but not yet approved for pharmaceutical use. It is a prodrug of ribavirin, active against a number of DNA and RNA viruses. Taribavirin has better liver-targeting than ribavirin, and has a shorter life in the body due to less penetration and storage in red blood cells. It is expected eventually to be the drug of choice for viral hepatitis syndromes in which ribavirin is active. These include hepatitis C and perhaps also hepatitis B and yellow fever.
dbpprop:atcPrefix
  • J05
dbpprop:atcSuffix
  • AB04
dbpprop:bioavailability
  • 9
dbpprop:c
  • 8 (xsd:integer)
dbpprop:casNumber
  • 119567-79-2
dbpprop:drugbank
  • none
dbpprop:eliminationHalfLife
  • 12 days - Multiple Dose; 120-170 hours - Single Dose
dbpprop:excretion
  • 10% fecal, remainder in urine (30% unchanged, remainder metabolites)
dbpprop:h
  • 13 (xsd:integer)
dbpprop:hasPhotoCollection
dbpprop:iupacName
  • 1-[(2R,3R,4S,5S)- 3,4-dihydroxy-5- (hydroxymethyl)oxolan-2-yl]- 1,2,4-triazole-3-carboximidamide
dbpprop:legalStatus
  • In Phase III drug trials
dbpprop:metabolism
  • Metabolized to 5'phosphates, de-riboside, and deriboside carboxylic acid
dbpprop:molecularWeight
  • 243.220 g/mol
dbpprop:n
  • 5 (xsd:integer)
dbpprop:o
  • 4 (xsd:integer)
dbpprop:pregnancyCategory
  • X
dbpprop:pubchem
  • 451448 (xsd:integer)
dbpprop:routesOfAdministration
  • Oral capsule
dbpprop:synonyms
  • 1-(β-D-Ribofuranosyl)- 1,2,4-triazole-3-carboximide
dbpprop:width
  • 134 (xsd:integer)
dbpprop:wikiPageUsesTemplate
rdf:type
rdfs:comment
  • Taribavirin (rINN; also known as viramidine, codenamed ICN 3142) is an antiviral drug in Phase III human trials, but not yet approved for pharmaceutical use. It is a prodrug of ribavirin, active against a number of DNA and RNA viruses. Taribavirin has better liver-targeting than ribavirin, and has a shorter life in the body due to less penetration and storage in red blood cells. It is expected eventually to be the drug of choice for viral hepatitis syndromes in which ribavirin is active.
rdfs:label
  • Taribavirin
owl:sameAs
skos:subject
foaf:depiction
foaf:page
is dbpprop:redirect of
is owl:sameAs of